drug · antibody
sarilumab
Phase 2updated 3mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and immune system disease and 10 investigational indications.
indications
indications
Rheumatoid Arthritis
targets
Interleukin-6 receptor subunit alpha
all catalysts(0)
nothing on the calendar yet
Trials studying sarilumab
- phase2A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- phase2Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- phase2Phase 1b/2 Study of IV Sarilumab in Adult With RA
- phase2Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- phase1A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
- phase2A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
- phase2A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
- phase4Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 47m ago
Found something off?
comments(0)
5-min edit window · permanent after that